Regular ArticleRadiation Therapy of Pelvic Recurrence after Radical Hysterectomy for Cervical Carcinoma
References (23)
- et al.
Rationale for using pathologic tumor dimensions and nodal status to subclassify surgically treated stage IB cervical cancer patients
Gynecol Oncol
(1991) - et al.
Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix
Gynecol Oncol
(1989) - et al.
Radical hysterectomy and pelvic lymphadenectomy for the management of early invasive cancer of the cervix
Gynecol Oncol
(1976) - et al.
Recurrent cervical carcinoma after radical hysterectomy
Gynecol Oncol
(1988) - et al.
Optimal therapy for pelvic recurrence after radical hysterectomy for early-stage cervical cancer
Gynecol Oncol
(1990) - et al.
Treatment of locoregional recurrence of carcinoma of the cervix by radiotherapy after primary surgery
Gynecol Oncol
(1989) - et al.
Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors
Int J Radiat Oncol Biol Phys
(1996) - et al.
Carcinoma in episiotomy scars
Gynecol Oncol
(1992) - et al.
Squamous cell carcinoma of the cervix implanting in the episiotomy site
Gynecol Oncol
(1993) - et al.
Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma
Gynecol Oncol
(1995)
Concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after radical surgery
Gynecol Oncol
(1987)
Cited by (81)
Invasive cervical cancer
2023, DiSaia and Creasman Clinical Gynecologic OncologyComputed Tomography-Based Interstitial Brachytherapy for Recurrent Cervical Carcinoma in the Vaginal Apex
2022, Clinical OncologyCitation Excerpt :Disease-free survival (DFS) after radiotherapy is 40–50% in patients with localised central pelvic recurrence. However, when the recurrences are nodal or in the pelvic sidewalls, DFS is only 12–15% after radiotherapy [6–9]. This suggests that the radiation dose delivered presently may not be sufficient to obtain adequate local control in all cases, particularly in the presence of pelvic sidewall disease, and also that the recurrent tumours may have an aggressive feature that limits their radiocurability.
Molecular landscape of recurrent cervical cancer
2021, Critical Reviews in Oncology/HematologyCancers of the Cervix, Vulva, and Vagina
2019, Abeloff’s Clinical OncologyInvasive cervical cancer
2018, Clinical Gynecologic OncologyCervical Cancer
2015, Clinical Radiation Oncology
- 1
To whom reprint requests should be addressed. Fax (713) 792-3642.
Copyright © 1998 Academic Press. All rights reserved.